Mainz Biomed (NASDAQ:MYNZ – Free Report) shares are scheduled to reverse split on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 2nd.
Mainz Biomed Stock Performance
Shares of NASDAQ:MYNZ traded down $0.04 on Friday, reaching $0.22. 7,094,717 shares of the company were exchanged, compared to its average volume of 1,350,238. Mainz Biomed has a 1-year low of $0.19 and a 1-year high of $1.79. The company has a 50-day moving average of $0.26 and a 200-day moving average of $0.39.
Analyst Ratings Changes
Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Why Are Stock Sectors Important to Successful Investing?
- 3 Penny Stocks Ready to Break Out in 2025
- The 3 Best Fintech Stocks to Buy Now
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
